«12345»Seite
5 articles with references, page 2 of 5

Review article

End Organ Damage In Hypertension

Dtsch Arztebl Int 2010; 107(49): 866-73; DOI: 10.3238/arztebl.2010.0866

Schmieder, R E

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747–57. MEDLINE
2. Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Foerce document. J Hypertens 2009; 27: 2121–58. MEDLINE
3. Deutsche Hochdruckliga e.V.: Leitlinien zur Behandlung der arteriellen Hypertonie. Nieren- und Hochdruckkrankheiten 2009; 38: 137–88.
4. Schmieder RE: The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant 2005; 20: 2610–2. MEDLINE
5. Laurent S, Boutouyrie P: Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol 2007; 20(suppl 12): 45–50. MEDLINE
6. Williams B, Lacy PS, Thom SM, et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–25. MEDLINE
7. Schmieder RE, Messerli FH: Hypertension and the heart. J Hum
Hypertens 2000; 14: 597–604. MEDLINE
8. Motz W, Scheler S, Schwartzkopff B, Strauer BE: Evaluation of cardiac damage in hypertension. J Cardiovasc Risk 1995; 2: 16–26. MEDLINE
9. Schwab J, Schneider MP, Pauschinger M, Schmieder RE: Hypertension and diastolic dysfunction. MMW Fortschr Med 2009; 151: 41–3. MEDLINE
10. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B: Effect of
obesity on electrocardiographic left ventricular hypertrophy in
hypertensive patients : the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000; 35: 13–8. MEDLINE
11. Verdecchia P, Reboldi G, Gattobigio R, et al.: Atrial fibrillation in
hypertension: predictors and outcome. Hypertension 2003; 41: 218–23. MEDLINE
12. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–6. MEDLINE
13. Verdecchia P, Angeli F, Borgioni C, et al.: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895–9. MEDLINE
14. Chen X, Wen W, Anstey KJ, Sachdev PS: Prevalence, incidence, and risk factors of lacunar infarcts in a community sample. Neurology 2009; 73: 266–72 MEDLINE
15. van den Born BJ, Hulsman CA, Hoekstra JB, Schlingemann RO, van Montfrans GA: Value of routine funduscopy in patients with hypertension: systematic review. BMJ 2005; 331: 73. MEDLINE
16. Michelson G, Welzenbach J, Pal I, Harazny J: Automatic full field analysis of perfusion images gained by scanning laser Doppler flowmetry. Br J Ophthalmol 1998; 82: 1294–300. MEDLINE
17. Zanchetti A, Mancia G, Black HR, et al.: Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens 2009; 27: 673–9. MEDLINE
18. Leoncini G, Ratto E, Viazzi F, et al.: Global risk stratification in
primary hypertension: the role of the kidney. J Hypertens 2008; 26: 427–32. MEDLINE
19. Schmieder RE, Schrader J, Zidek W, et al.: Subclinical albuminuria, microalbuminuria and proteinuria-accepted cardiovascular risk markers? Dtsch Med Wochenschr 2006; 131: 2665–71. MEDLINE
20. Ninomiya T, Perkovic V, de Galan BE, et al.: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813–21. MEDLINE
21. Levey AS, Cattran D, Friedman A, et al.: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205–26. MEDLINE
22. Ibsen H, Olsen MH, Wachtell K, et al.: Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive
patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198–202. MEDLINE
23. de Zeeuw D, Remuzzi G, Parving HH, et al.: Albuminuria, a
therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–7. MEDLINE
24. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). J Am Soc Nephrol 1998; 9: 2096–101. MEDLINE
25. Messerli FH, Mancia G, Conti CR, et al.: Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144: 884–93. MEDLINE
e1. Mancia G, Bombelli M, Facchetti R, et al.: Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54: 226–32. MEDLINE
e2. Schmieder RE, Langenfeld MR, Friedrich A, Schobel HP, Gatzka CD, Weihprecht H: Angiotensin II related to sodium excretion
modulates left ventricular structure in human essential hypertension. Circulation 1996; 94: 1304–9. MEDLINE
e3. Messerli FH, Schmieder RE, Weir MR: Salt. A perpetrator of hypertensive target organ disease? Arch Intern Med 1997; 157: 2449–52. MEDLINE
e4. Shokawa T, Imazu M, Yamamoto H, et al.: Pulse wave velocity
predicts cardiovascular mortality: findings from the Hawaii-Los Angeles-Hiroshima study. Circ J 2005; 69: 259–64. MEDLINE
e5. Laurent S: Hypertension and macrovascular disease. European Society of Hypertension Scientific Newsletter 2007; 8(31): 1–2. (12. 8. 2010).
e6. Dahlof B, Sever PS, Poulter NR, et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895–906. MEDLINE
e7. Messerli FH, Grossman E, Goldbourt U: Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A
systematic review. JAMA 1998; 279: 1903–7. MEDLINE
e8. Agabiti-Rosei E, Muiesan ML, Salvetti M: Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy. J Am Soc Nephrol 2006; 17: 104–8. MEDLINE
e9. Alfakih K, Walters K, Jones T, Ridgway J, Hall AS, Sivananthan M: New gender-specific partition values for ECG criteria of left
ventricular hypertrophy: recalibration against cardiac MRI.
Hypertension 2004; 44: 175–9. MEDLINE
e10. Lang RM, Bierig M, Devereux RB, et al.: Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108. MEDLINE
e11. Palmieri V, Dahlof B, DeQuattro V, et al.: Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement. J Am Coll Cardiol 1999; 34: 1625–32. MEDLINE
e12. Eriksson SE, Olsson JE: Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovasc Dis 2001; 12: 171–80. MEDLINE
e13. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13. MEDLINE
e14. Schmieder RE: Hypertensive retinopathy. European Society of
Hypertension Scientific Newsletter 2009; 10(14): 1–2. (12. 8. 2010).
e15. Dimmitt SB, West JN, Eames SM, Gibson JM, Gosling P, Littler WA: Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet 1989; 1: 1103–6. MEDLINE
e16. Wong TY, Mitchell P: Hypertensive retinopathy. N Engl J Med 2004; 351: 2310–7. MEDLINE
e17. Sleight P, Redon J, Verdecchia P, et al.: Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmi-sartan alone and in combination with ramipril global endpoint trial study. J Hypertens 2009; 27: 1360–9. MEDLINE
e18. Turan TN, Cotsonis G, Lynn MJ, Chaturvedi S, Chimowitz M: Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation 2007; 115: 2969–75. MEDLINE
e19. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97. MEDLINE
e20. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36. MEDLINE
e21. Hallan SI, Ritz E, Lydersen S, Romundstad S, Kvenild K, Orth SR: Combining GFR and albuminuria to classify CKD improves prediction of ESRD. J Am Soc Nephrol 2009; 20: 1069–77. MEDLINE
e22. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R: First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20: 436–43. MEDLINE
e23. Arnlov J, Evans JC, Meigs JB, et al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969–75. MEDLINE
e24. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK: Aliskiren combined with losartan in type 2 diabetes and nephropathy.
N Engl J Med 2008; 358: 2433–46. MEDLINE
e25. Laurent S, Cockcroft J, Van Bortel L, et al.: Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–605. MEDLINE